Another insurance company continues to rate the WVU Cancer Institute Osborn Hematopoietic Malignancy and Transplantation Program as excellent. Highmark Blue Cross Blue Shield in West Virginia recently notified the program that it has received the company’s Blue Distinction Centers for Transplants Designation, which denotes commitment to delivering quality specialty care safely, effectively and cost efficiently. This marks the second consecutive time the Cancer Institute has received the designation from Highmark. “This validates that our program continues to provide superior care,” Sonia Leadmon, oncology quality coordinator at the Cancer Institute Mary Babb Randolph Cancer Center, said.
The health insurer took into consideration patient volume, transplant quality outcomes and additional accreditations the program has previoulsly received from other agencies.
Dental school's tobacco treatment training program will host its third continuing education course in May 2020.
WVU in the News: Industry cites 3M research on cancer patients exposed to PFOA to claim them chemical isn't so bad
Defenders of the chemicals known as PFAS have seized upon an industry-funded study of cancer patients as evidence that PFOA, the compound used to make Teflon, firefighting foam, and many other products, isn’t as dangerous as it seems.
Sumaira Shafi, M.D., has joined the hematology/oncology staff at Camden Clark Regional Cancer Center, a WVU Cancer Institute location.